The european myeloma network and karyopharm announce dosing of first patient in collaborative emn29/xport-mm-031 study

- phase 3 study evaluating an all oral regimen of selinexor in combination with pomalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma - rotterdam, netherlands and newton, mass. , may 25, 2022 /prnewswire/ -- the european myeloma network (emn), an international collaborative network of expertise centers for multiple myeloma in europe and australia, and karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the dosing of the first patient in the collaborative emn29/xport-mm-031 study, a randomized, global phase 3 study evaluating an all-oral regimen of selinexor, karyopharm's first-in-class, oral exportin 1 (xpo1) inhibitor, in combination with pomalyst® (pomalidomide) and low-dose dexamethasone (spd) versus empliciti® (elotuzumab), pomalidomide, and dexamethasone (epd) in patients with relapsed or refractory multiple myeloma (nct05028348//emn29).
KPTI Ratings Summary
KPTI Quant Ranking